Prognostic role of the combination of platelet count and neutrophil-lymphocyte ratio in patients with hypopharyngeal squamous cell carcinoma

Prognostic role of the combination of platelet count and neutrophil-lymphocyte ratio in patients with hypopharyngeal squamous cell carcinoma
复制标题

DOI:
10.1007/s00405-016-3996-3
复制
发表时间:
2016-11-01
影响因子:
2.6
通讯作者:
Kogashiwa, Yasunao
Kogashiwa, Yasunao
中科院分区:
医学3区
文献类型:
--
作者:
Nakahira, Mitsuhiko;Sugasawa, Masashi;Kogashiwa, Yasunao

文献摘要

被引文献

相似文献

下咽鳞状细胞癌(HPSCC)是一种侵袭性疾病,预后不良;但尚未确定口咽癌中人乳头瘤病毒和 p16 等生物标志物。本研究调查了治疗前血清标志物,包括血小板计数和中性粒细胞-淋巴细胞比值 (COP-NLR) 的组合,作为我院治疗的 HPSCC 患者的预后预测因子。我们回顾性审查了 2007 年至 2013 年间在我院连续接受治疗的 118 名患者的电子病历。在这 118 名患者中,我们招募了 100 名患者,我们有足够的数据来分析临床实验室特征与生存之间的关系,包括治疗前血清标志物和先前报告的临床因素的预后意义。对临床实验室特征的多变量分析将 COP-NLR 与癌症特异性生存相关,淋巴结转移也是如此。 Kaplan-Meier 分析和时序检验表明 COP-NLR 可以将这些患者分为三个独立组(P = 0.003)。 COP-NLR 可能是 HPSCC 患者生存的有用预测因子。
Hypopharyngeal squamous cell carcinoma (HPSCC) is an aggressive disease with poor prognosis; but has no established biomarkers on the order of human papilloma virus and p16 in oropharyngeal carcinoma. This study investigated pre-treatment serum markers, including the combination of platelet count and neutrophil-lymphocyte ratio (COP-NLR) as a prognosis predictor in patients with HPSCC treated in our hospital. We retrospectively reviewed electronic medical records of 118 consecutive patients treated with curative intent at our hospital between 2007 and 2013. Of these 118 patients, we enrolled 100 patients for whom we had sufficient data to analyze relationships between clinico-laboratory characteristics and survival, including the prognostic significance of pre-treatment serum markers and previous reported clinical factors. Multivariate analysis of clinico-laboratory characteristics associated COP-NLR with cancer-specific survival, as were lymph node metastases. Kaplan-Meier analysis and log-rank tests showed that the COP-NLR could stratify those patients into three independent groups (P = 0.003). COP-NLR might be a useful predictor of survival in patients with HPSCC.